Previous Close | 0.3000 |
Open | 0.3000 |
Bid | 0.0000 |
Ask | 4.9000 |
Strike | 50.00 |
Expire Date | 2024-08-16 |
Day's Range | 0.3000 - 0.3000 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, for the treatment of pediatric and adult patients with neurofibromatosis type 1- associated plexiform neurofibromas (NF1
On June 3, 2024, Julie Hambleton, Director at SpringWorks Therapeutics Inc (NASDAQ:SWTX), sold 4,648 shares of the company.
Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics Inc (NASDAQ:SWTX), sold 20,000 shares of the company on June 3, 2024, according to a recent SEC filing.